The study developed and validated ⁸⁹Zr-labeled ivuxolimab, an anti-human OX40 antibody, for PET imaging of activated T cells. In human OX40 Knockin mice, tracer accumulation correlated with T cell activation in a graft-versus-host disease (GVHD) model. Ex vivo and in vivo PET/CT analyses confirmed high specificity and functional readout of OX40 engagement.
⁸⁹Zr‑ivuxolimab binds activated T cells in vivo, enables longitudinal imaging of OX40⁺ populations in inflammatory models, supports translational development of OX40-targeted immunotherapies
Human OX40 Knockin mouse — genOway-developed, expressing human OX40 (TNFRSF4) to replace mouse OX40, allowing in vivo detection of human OX40 with ⁸⁹Zr-ivuxolimab
Immuno-PET imaging, T cell activation, humanized immune targets, GVHD model, translational imaging biomarkers
Human OX40 gene Knockin, replacement of murine Tnfrsf4 with human sequence, PET tracer (⁸⁹Zr‑ivuxolimab), GVHD-induced activation model, in vivo T cell tracking, radiolabeling and biodistribution
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
